Catalent (NYSE:CTLT) Receives New Coverage from Analysts at StockNews.com

Analysts at StockNews.com initiated coverage on shares of Catalent (NYSE:CTLT) in a research note issued on Thursday. The brokerage set a “sell” rating on the stock.

Other analysts have also recently issued research reports about the stock. Barclays increased their price target on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. William Blair reaffirmed a “market perform” rating on shares of Catalent in a report on Tuesday, September 3rd. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $63.50 target price on shares of Catalent in a report on Thursday, July 11th. Robert W. Baird reaffirmed a “neutral” rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday. Finally, Baird R W cut shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday. One analyst has rated the stock with a sell rating and eight have given a hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $59.83.

Catalent Stock Down 0.5 %

Shares of CTLT opened at $59.86 on Thursday. The stock has a market capitalization of $10.86 billion, a PE ratio of -9.81, a P/E/G ratio of 2.32 and a beta of 1.15. Catalent has a 1 year low of $31.80 and a 1 year high of $61.20. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52. The company’s 50-day simple moving average is $59.60 and its 200-day simple moving average is $57.29.

Catalent (NYSE:CTLT) last issued its quarterly earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.44 by $0.13. The business had revenue of $1.30 billion for the quarter, compared to analysts’ expectations of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. Analysts forecast that Catalent will post 0.85 earnings per share for the current fiscal year.

Insider Activity at Catalent

In related news, SVP Scott Gunther sold 666 shares of Catalent stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total value of $39,660.30. Following the transaction, the senior vice president now directly owns 39,635 shares in the company, valued at approximately $2,360,264.25. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In other Catalent news, SVP Scott Gunther sold 666 shares of the firm’s stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.55, for a total value of $39,660.30. Following the completion of the sale, the senior vice president now owns 39,635 shares of the company’s stock, valued at $2,360,264.25. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Ricky Hopson sold 662 shares of Catalent stock in a transaction on Friday, August 2nd. The stock was sold at an average price of $59.56, for a total value of $39,428.72. Following the transaction, the insider now directly owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The disclosure for this sale can be found here. Insiders have sold a total of 13,409 shares of company stock worth $782,923 in the last three months. Insiders own 0.31% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in CTLT. Gamco Investors INC. ET AL grew its holdings in Catalent by 403.3% in the 1st quarter. Gamco Investors INC. ET AL now owns 25,300 shares of the company’s stock valued at $1,428,000 after buying an additional 20,273 shares during the period. BNP PARIBAS ASSET MANAGEMENT Holding S.A. grew its holdings in Catalent by 2,792.9% in the 1st quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 516,390 shares of the company’s stock valued at $29,150,000 after buying an additional 498,540 shares during the period. UniSuper Management Pty Ltd grew its holdings in Catalent by 509.4% in the 1st quarter. UniSuper Management Pty Ltd now owns 18,204 shares of the company’s stock valued at $1,028,000 after buying an additional 15,217 shares during the period. Swedbank AB purchased a new stake in Catalent in the 1st quarter valued at about $1,659,000. Finally, SG Americas Securities LLC grew its holdings in Catalent by 147.4% in the 1st quarter. SG Americas Securities LLC now owns 99,588 shares of the company’s stock valued at $5,622,000 after buying an additional 59,339 shares during the period.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.